Pharmacogenomics in clinical practice: CYP phenotypes, PGx testing, and GP case pathways
A GP-facing summary of how common gene variants shape drug response — CYP metabolizer phenotypes, what a PGx panel actually tests, Medicare’s narrow MBS listings, traffic-light reports, Charlotte’s SSRI pathway, Charlene’s clopidogrel case, RCPA indicators, and practice resources — from an exhibition-style clinical genomics talk.
- Primary speaker
- Speaker 1 in Otter — name not clearly stated. Session context points to Bertha / Bupa Health Services clinical genomics and an Alpha Coach genomics exhibition upskilling offer (cheek-swab opportunity at the venue). Do not invent a doctor surname.
- Session context
- Otter id
jedwjws2LYRWDl5f0M5eZdRhFQg· title Pharmacogenomics in Clinical Practice · ~22 min · single speaker. Closing invitation to try a personal swab at the exhibition stand; data described as staying onshore and not used for health insurance.
Key messages for GPs
- Roughly 30–40% of medication response variability is attributed to genetic variation; nearly everyone carries at least one variant that can matter for some drug.
- CYP450 enzymes dominate oxidative drug metabolism; a handful of isoforms handle most everyday prescriptions. Phenotypes range from poor → intermediate → normal → rapid / ultrarapid metabolizers — with opposite risks for active drugs versus prodrugs.
- Commercial PGx panels are usually a cheek swab, focused variant testing (not whole-gene sequencing), results in about 2–3 weeks, often out-of-pocket. Current MBS listings are narrow (HIV-related and selected oncology dose-toxicity genes).
- Reports commonly use a traffic-light framing (major flag / nuanced / usual metabolism) with links to CPIC / ClinPGx-style guidance.
- Worked examples: Charlotte — CYP2C19 poor metabolizer on an SSRI pathway with dose/alternative implications, plus SLCO1B1 findings relevant to future statin choice; Charlene — CYP2C19 no-function genotype making clopidogrel a poor fit after MI.
- RCPA pharmacogenomic testing indicators (reviewed periodically) flag medications where testing should be paused-for or considered before prescribing — including commonly used agents such as amitriptyline, tamoxifen, tramadol, and warfarin in the talk’s examples.
Why PGx matters nationally
The speaker opened with scale: about 250,000 Australians are admitted each year for adverse drug reactions and/or treatment failure, and up to 50% of medication-related harm is framed as preventable through better education, risk assessment, and prescribing processes. Medication safety is a national priority. A projection cited from the ACHR suggested up to $6.2 billion could be saved over five years with pharmacogenomic-guided medication decisions.
This is not “test everyone tomorrow.” It is a shift from pure trial-and-error toward using genotype when the drug class, polypharmacy load, or prior ADRs make a one-size-fits-all start less sensible — within Australian access and cost realities.
What pharmacogenomics is
Pharmacogenomics sits at the intersection of pharmacology and precision medicine: how common genetic variants change response to medicines. Genetics is multifactorial alongside age, comorbidities, adherence, and drug–drug interactions — but genomics is a foundational piece of metabolism thinking. The speaker emphasised that almost every person, regardless of background, carries variants that will affect some medication response.
CYP enzymes and metabolizer phenotypes
The cytochrome P450 superfamily encodes enzymes that drive much of oxidative (phase I) metabolism. The speaker noted about six key isoforms handling roughly 80–90% of therapeutic drug metabolism — highly relevant to everyday GP prescribing. Attention was drawn especially to CYP3A4 and CYP2D6 as accounting for a large share of clinically important metabolism, drug–drug interactions, and drug-development focus. Across the CYP family there are over 350 functional polymorphisms — these genes are highly variable.
Approximate population framing from the talk:
- About 1 in 10 people are poor metabolizers for one or more relevant pathways (little or no functional enzyme for that isoform) — higher side-effect / toxicity risk for many active drugs; lower activation (and less efficacy) for many prodrugs.
- About 1 in 3 are framed as extensive / high-level (rapid) metabolizers — may struggle to reach therapeutic levels of an active drug at standard dose, or form active metabolite too quickly from a prodrug with more adverse-effect risk.
| Phenotype (broad) | Active drug (many CYP substrates) | Prodrug needing CYP activation |
|---|---|---|
| Poor metabolizer | Higher exposure → side-effects / toxicity risk at standard dose | Less active metabolite → reduced efficacy |
| Rapid / ultrarapid | May not reach therapeutic levels at standard dose | Rapid active metabolite → adverse-effect risk |
| Normal / typical | Usually guideline-standard dosing is a reasonable starting point (still watch interactions and clinical response) | |
How testing works in Australia
A pharmacogenomic (PGx) test targets common polymorphisms / alleles to support more individualised prescribing. Multiple providers operate across Australia / the Pacific with differences in accreditation, data location, and how they engage clinicians. Shared steps described:
- Order — clinician- or patient-initiated; Medicare billing is limited, so out-of-pocket cost is common; some providers ask the patient to nominate their GP for results.
- Sample — most often a non-invasive cheek swab.
- Lab analysis — focused variant testing, not complete sequencing of every relevant gene; panels differ in gene count; no commercial test covers all drug–gene pairs or drug allergies.
- Results — typically 2–3 weeks; ideally interpreted by a GP who knows the patient’s history within a routine clinical pathway.
Current MBS listings for this space were described as highly targeted: one pathway related to HIV treatment, and others focused on dose-related toxicity risk in cancer / leukaemia contexts. Further applications were said to be under evaluation (MSAC). Useful where they apply — but they leave a real access and cost gap for broader GP use of PGx panels.
Reading a traffic-light report
Most provider reports use a traffic-light system:
- Red / major flag — clinically important finding; high likelihood of adverse reaction or poor therapeutic benefit for a class or drug; often tied to poor or ultrarapid metabolizer status.
- Orange / amber — nuanced interpretation needed.
- Green — essentially normal / typical metabolism for that pathway.
An example report in the talk flagged warfarin with two relevant genes showing low / no-function metabolizer status, plus prescribing recommendations and links to guidelines (CPIC-style guidance via ClinPGx was highlighted as a useful international consensus resource).
Case: Charlotte (mental health + future statin risk)
Charlotte is a 48-year-old woman, partnered, no children, full-time work. She has a ~30-year history of persistent depression, engages in psychotherapy, and was recently started on an antidepressant at 100 mg daily (Otter ASR garbled the drug name; context is an SSRI pathway with prior similar GI intolerance — treat the exact brand/generic as uncertain unless confirmed in the source materials). She has no other major personal history but a family history of high cholesterol.
She returns with difficulty sleeping, transient diarrhoea, and low-level nausea since starting the new prescription. She previously tried another SSRI (Otter: “silvopam” — commonly heard as escitalopram in this context) with similar gastrointestinal issues. She asks about pharmacogenomic testing to understand response and plan next steps.
Results discussed
- CYP2C19 — two low / no-function alleles → poor metabolizer for relevant CYP2C19 substrates, including the SSRI pathway discussed. Guideline-style recommendation in the talk: the 100 mg dose should be lowered to under 75 mg/day, or consider an alternative — then review whether GI and sleep symptoms improve.
- SLCO1B1 (Otter: “SRCO one b1”) — again two reduced-function alleles → poor transporter phenotype for certain statins (example named: atorvastatin). Recommendation if a statin is considered later: lower dose or a different approach — valuable anticipatory information given her family history of high cholesterol even though she has no current lipid presentation.
Overseas estimates cited: up to ~50% of patients do not respond well (or at all) to the first antidepressant trialled. Trial-and-error raises cost, disengagement risk, and treatment-resistant depression risk. A UK study mentioned found patients prescribed antidepressants with PGx guidance were about 70% more likely to achieve remission than those without PGx information.
Case: Charlene (clopidogrel after MI)
Charlene, Charlotte’s mother, is 71, retired, with another adult child besides Charlotte. She recently had a heart attack while gardening. On discharge she was prescribed clopidogrel. Charlotte brings her to the GP to discuss ongoing cardiovascular risk management.
The GP checks RCPA indications and finds a strong recommendation for PGx testing before starting clopidogrel. Testing proceeds. Result framed in the talk: Charlene is homozygous for a no-function allele (described as the “*2” version) — again a poor metabolizer for clopidogrel — meaning significantly reduced active-metabolite formation and higher risk of adverse cardio / cerebrovascular events on that agent. Recommendation: avoid clopidogrel and choose an alternative. The speaker cited roughly a 5–16% chance of a second cardiac event on clopidogrel with this genotype pattern — described as a high-prevalence, practical use case.
Who to consider for testing
Clinical flags highlighted for considering PGx when available:
- People experiencing adverse effects or poor response on current medicines
- About to start or switch a medication in a PGx-relevant class
- Polypharmacy — especially chronic disease and pain management on multiple agents
- Personal or family history suggesting future medication choices in cardiovascular disease, mental health, attention disorders, pain, or gastrointestinal symptom pathways
RCPA indicators and practice resources
Despite potential benefit for patients and for reducing repeat “doesn’t work / side-effect” appointments, PGx remains underutilised in Australian general and specialty practice. At a prior HealthEd audience poll cited, most attendees lacked confidence ordering or interpreting PGx. Education, cost, and equity gaps were named.
In October of the prior year (relative to the talk), the RCPA published indicators for pharmacogenomic testing for Australian healthcare providers (due for review again the following year). These consensus indicators list medicines where clinicians should pause or reflect and consider PGx data before proceeding — tied to drugs available in Australia and linked to CPIC guidance via ClinPGx. About 21 drugs sat in recommend / consider categories at the time of the talk. Examples named: amitriptyline, tamoxifen, tramadol, warfarin.
Practice resources flagged:
- RACGP genomics in general practice guidance (includes pharmacogenomic advice)
- Centre for Genomics Education (NSW) materials on PGx in general and specialty practice
- Primary-care genomics education platforms (precise product name ASR-garbled)
- Pharmacists — Home Medicines Reviews (HMR) can incorporate PGx considerations; overseas data cited better adherence and outcomes when PGx is integrated into medication review
- Labs such as Genomic Diagnostics, Sonic, and Bertha — some have genetic counsellors available for result questions
- Genetic services / providers for additional support
The speaker invited attendees to try a personal cheek swab via Bertha at the Alpha Coach genomics stand — framed as experiential learning for interpreting one’s own report. Data described as staying onshore, not used for health insurance, and not accessed by Bupa for that purpose. Treat as session context, not a prescribing recommendation.
- All CPD lectures index
- Dyslipidemia — lipid therapy context when SLCO1B1 / statin pathways arise
- Cardiovascular and diabetes
- Cognitive assessment — broader medicines-in-older-adults framing